Search

1 to 10 of 19
Sort by

Blog Entry
Second policy test blog

This is the second policy test blog. #Policy ​

Adam Wise's profile image

Blog Entry
Policy test post (May 12, 2020)

This is a test post for the policy blog. #Policy ​

Adam Wise's profile image

Library Entry
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)...


Library Entry
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most likely to respond to immune checkpoint inhibitors. TMB is optimally calculated...


Library Entry
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...


Library Entry
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Using the National Cancer Database, the authors identified 4725 patients aged ≥20 diagnosed with...


Library Entry
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost...


Library Entry
Adoptive Cellular Therapies Workshop - Friday Presentations

Available here are the presentation slides and video recordings from the Friday, September 6, 2019 Adoptive Cellular Therapies Workshop. In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of patients with...

9 attachments


Library Entry
Adoptive Cellular Therapies Workshop - Thursday Presentations

Available here are the presentation slides and video recordings from the Thursday, September 5, 2019 Adoptive Cellular Therapies Workshop. In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of patients with...

21 attachments


Library Entry
The promise of Immuno-oncology: implications for defining the value of cancer treatment

The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies,...